US 12,251,234 B2
Systems and methods for transdermally detecting tissue ischemia and evaluating organ function using serum luminescence
Tzu-Ming Liu, Taipa (CN)
Assigned to University of Macau, Taipa (CN); and CATYDID Technology Ltd., Taipa (CN)
Filed by University of Macau, Taipa (CN); and CATYDID Technology Ltd., Taipa (CN)
Filed on Sep. 20, 2019, as Appl. No. 16/577,996.
Claims priority of provisional application 62/734,961, filed on Sep. 21, 2018.
Prior Publication US 2020/0093415 A1, Mar. 26, 2020
Int. Cl. A61B 5/00 (2006.01); G01N 21/64 (2006.01)
CPC A61B 5/4244 (2013.01) [A61B 5/0071 (2013.01); A61B 5/489 (2013.01); A61B 5/7203 (2013.01); G01N 21/6428 (2013.01); G01N 2021/6417 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A method of detecting tissue ischemia, comprising:
repeatedly or constantly measuring an emission intensity of the endogenous serum chromophore transdermally from blood contemporaneously with a real time detection that the intensity or temporal change of intensity of the endogenous serum chromophore has exceeded a threshold intensity level or temporal gradient;
directing an excitation light from a continuous wave laser at the serum,
wherein the excitation light is configured to produce an excitation wavelength between 340-480 nm;
receiving an endogenous serum chromophore emission light from the excited serum by an objective lens and/or photodetector positioned to receive the luminescence signals from the endogenous chromophore,
wherein the endogenous serum chromophore emission light received from the excited serum is captured at a single photon spectrometer,
wherein the endogenous serum chromophore emission light received from the excited serum has an emission wavelength between 400-650 nm; and
determining a presence of an ischemic condition based on an intensity or a temporal change of the endogenous serum chromophore emission light by calibrating and normalizing the intensity of the endogenous serum chromophore emission light to scattering light around 467 nm and measuring a peak fluorescence intensity between 400-650 nm;
wherein determining the presence of the ischemic condition comprises calculating an optical index, the optical index comprising an arithmetic calculation of spectral and temporal variation of intensities at a plurality of wavelengths that are each associated with a principal chromophore component, determined from an excitation wavelength swept fluorescence spectra of the blood sample;
wherein based on a first determination that the ischemic condition is present, the method further comprises conducting an in vitro assay of serum marker proteins to confirm a type and/or anatomical location of the tissue ischemia, and wherein based on a second determination that the ischemic condition is not present, the method comprises monitoring the endogenous serum chromophore emission light of serum isolated at later timepoints.